StockData
Prime Medicine, Inc. logo

Prime Medicine, Inc. (PRME) stock

PRMENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.82−0.02 (-0.52%)

Close on Nov 18, 2026Market cap $692.86MP/E –Yield –

Prime Medicine operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Prime Medicine's operating income for the twelve months ending Jun 30, 2026 was -$196.52M. For fiscal 2025 it was -$208.35M. The highest annual figure on record is -$932.00K in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$208.35M–
FY2024Dec 31, 2024-$202.47M–
FY2023Dec 31, 2023-$204.79M–
FY2022Dec 31, 2022-$116.54M–
FY2021Dec 31, 2021-$84.47M–
FY2020Dec 31, 2020-$932.00K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$43.29M–
Q1 FY2026Mar 31, 2026-$50.65M–
Q4 FY2025Dec 31, 2025-$48.61M–
Q3 FY2025Sep 30, 2025-$53.97M–
Q2 FY2025Jun 30, 2025-$53.38M–
Q1 FY2025Mar 31, 2025-$52.39M–
Q4 FY2024Dec 31, 2024-$44.22M–
Q3 FY2024Sep 30, 2024-$54.23M–
Q2 FY2024Jun 30, 2024-$55.67M–
Q1 FY2024Mar 31, 2024-$48.34M–
Q4 FY2023Dec 31, 2023-$68.04M–
Q3 FY2023Sep 30, 2023-$51.46M–
Q2 FY2023Jun 30, 2023-$45.26M–
Q1 FY2023Mar 31, 2023-$40.03M–
Q4 FY2022Dec 31, 2022-$38.69M–
Q3 FY2022Sep 30, 2022-$31.66M–
Q2 FY2022Jun 30, 2022-$26.31M–
Q1 FY2022Mar 31, 2022-$19.90M–
Q4 FY2021Dec 31, 2021-$60.08M–
Q3 FY2021Sep 30, 2021-$10.43M–

More Prime Medicine figures

See a number that looks wrong?